Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC multiple-dosing for refractory acute graft-versus-host disease
ChiCTR2200061603Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Any adverse events related to MSCs during the clinical study, Maximum tolerated dose and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2200061603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061603.